Casebia, Seattle Children's partner to develop gene-edited Tregs

Casebia Therapeutics (Cambridge, Mass.) and Seattle Children's Research Institute (Seattle, Wash.) partnered to develop CRISPR-Cas9 (CRISPR-associated protein 9)-edited Tregs to treat and prevent autoimmune

Read the full 247 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE